← ANALYST RATINGS · TIPRANKS
Resmed (RMD): analyst forecast and price target
Analyst consensus
Hold1 Buy4 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $228, the highest $240, the lowest $213. The average is −4.5% from the last price of $239.
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $235 → $240+2.1% | Buy | +0.4% | Assigned | 13.10.26on TipRanks 07:35 | +0.2%next day +1.2% | ↗ |
| Lyanne Harrison★★★★★★★★★★#10385 · hits 53% · avg −3.9% | Bank of America Securities | $320 | Buy | +33.9% | Reiterated | 13.10.26on TipRanks 05:45 | +0.2%next day +1.2% | ↗ |
| Jonathan Block★★★★★★★★★★#2320 · hits 50% · avg +5.3% | Stifel Nicolaus | $235 | Hold | −1.7% | Reiterated | 02.10.26on TipRanks 09:15 | −1.8%next day +1.1% · 5 days +3.9% | ↗ |
| Craig Wong-Pan★★★★★★★★★★#10044 · hits 46% · avg −1.5% | RBC Capital | $244 → $262+7.4% | Buy | +9.6% | Upgrade | 15.09.26on TipRanks 05:10 | +3.4%next day −0.1% · 5 days −5.6% | ↗ |
| Laura Sutcliffe★★★★★★★★★★#6428 · hits 51% · avg +1.0% | Citi | $235 → $240+2.1% | Hold | +0.4% | Reiterated | 10.09.26on TipRanks 06:40 | +0.4%next day −1.4% · 5 days +3.4% | ↗ |
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $263 → $266+1.1% | Buy | +11.3% | Reiterated | 06.09.26on TipRanks 13:05 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $263 → $265+0.8% | Buy | +10.9% | Reiterated | 06.09.26on TipRanks 13:05 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $257 → $261+1.6% | Buy | +9.2% | Reiterated | 06.09.26on TipRanks 13:05 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $250 → $260+4.0% | Buy | +8.8% | Reiterated | 06.09.26on TipRanks 13:05 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $261 → $264+1.1% | Buy | +10.5% | Reiterated | 06.09.26on TipRanks 13:05 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $261 → $268+2.7% | Buy | +12.1% | Reiterated | 06.09.26on TipRanks 13:05 | — | |
| Brett Fishbin★★★★★★★★★★#10514 · hits 45% · avg −3.0% | KeyBanc | $255 → $267+4.7% | Buy | +11.7% | Reiterated | 31.08.26on TipRanks 03:55 | +0.2%next day −3.0% · 5 days −7.8% | ↗ |
| Name not given | — | $230 | Hold | −3.8% | Initiated | 19.08.26on TipRanks 04:45 | +4.6%next day +0.2% · 5 days +2.9% | ↗ |
| Adam Maeder★★★★★★★★★★#1026 · hits 54% · avg +11.3% | Piper Sandler | $225 | Hold | −5.8% | Reiterated | 07.08.26on TipRanks 11:27 | −5.7%next day +3.9% · 5 days +5.5% | ↗ |
| Unknown Analyst | Oppenheimer | — | Hold | — | Assigned | 07.08.26on TipRanks 09:00 | −5.7%next day +3.9% · 5 days +5.5% | ↗ |
| David Rescott★★★★★★★★★★#3448 · hits 49% · avg +5.1% | Robert W. Baird | $217 → $213−1.8% | Hold | −10.9% | Reiterated | 07.08.26on TipRanks 08:10 | −5.7%next day +3.9% · 5 days +5.5% | ↗ |
| Nathan Treybeck★★★★★★★★★★#10843 · hits 28% · avg −5.3% | Wells Fargo | $225 → $215−4.4% | Hold | −10.0% | Assigned | 07.08.26on TipRanks 05:30 | −5.7%next day +3.9% · 5 days +5.5% | ↗ |
| Brandon Vazquez★★★★★★★★★★#11688 · hits 42% · avg −5.1% | William Blair | — | Buy | — | Reiterated | 07.08.26on TipRanks 03:05 | −5.7%next day +3.9% · 5 days +5.5% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | — | Hold | — | Reiterated | 07.08.26on TipRanks Aug 4 13:18 | +1.9%next day +0.6% · 5 days +0.9% | ↗ |
| David Bailey★★★★★★★★★★#3629 · hits 43% · avg +6.3% | Morgan Stanley | $230 | Hold | −3.8% | Reiterated | 13.07.26on TipRanks Jul 14 06:55 | −1.9%next day −3.1% · 5 days +1.0% | ↗ |
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $225 | Hold | −5.8% | Reiterated | 10.07.26on TipRanks 09:15 | −2.6%next day −1.9% · 5 days −0.8% | ↗ |
| Chris Cooper★★★★★★★★★★#2009 · hits 64% · avg +10.4% | J.P. Morgan | — | Buy | — | Initiated | 15.04.26on TipRanks Apr 16 06:13 | −1.6%next day −2.0% · 5 days −4.6% | ↗ |
| Unknown Analyst | Evercore ISI | $300 → $255−15.0% | Buy | +6.7% | Reiterated | 13.04.26on TipRanks 10:55 | −0.4%next day −1.0% · 5 days −5.1% | ↗ |
| Marcus Curley★★★★★★★★★★#12042 · hits 37% · avg −11.6% | UBS | $335 → $345+3.0% | Buy | +44.4% | Reiterated | 12.12.25on TipRanks Dec 14 03:25 | +1.0%next day +0.5% · 5 days −3.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Resmed
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $242 at a price of $221 (+9.5%); now: $245 at $239 (+2.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 3 | 2 | 2 | 2 | 2 |
| Hold | 6 | 6 | 11 | 9 | 9 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q1 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.68 (from $2.60 to $2.78). Last quarter: $2.95.
Sales
Next quarter’s sales estimate — $1.4B (from $1.4B to $1.4B). Last quarter: $1.5B.
Best top-analyst consensus in the sector · Healthcare
About Resmed
- CEO: Michael J. Farrell
- Employees: 11,370
- 9001 Spectrum Center Boulevard, San Diego, CA, 92123, US
- www.resmed.com
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
Data from the stock’s TipRanks forecast page, read 17 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗